



CURE PHARMTECH Co., LTD.

COMPANY PROFILE

www.curept.kr

Company Introduction

- OVERVIEW
- HISTORY
- BUSINESS INTRODUCTION

Overview

Company Name CURE PHARMTECH

CEO KIM, DAE-YOUNG

Established March 2015


Main business areas Medicine/medical device import distribution, Biopolymer business, Animal medicine business, Animal medicine clinical trials laboratory, Corporate-affiliated research institute, Cosmetic business etc.

No. of Employees 33 employees (51 including subsidiaries)

Address Headquarters_
#603, Hosu-ro 646-30, Ilsandong-gu, Goyang-si, Gyeonggi-do
Factory_
61, Donyu1-ro, Paju-eup, Paju-si, Gyeonggi-do (Sunyu Industrial Complex)



History



Introduction

CURE PHARMTECH_Headquarter

Based on the KGSP certification (Medical distribution management standards), we manage the overall work of Cure Pharmtech such as medicine, medical device distribution, import licensing, and subsidiary management.



Location	Janghang dong, Ilsandong-gu, Goyang-si, Gyeonggi-do
Major departments	General management, Sales, Marketing, Licensing, Development
Full-time employees	17 people
Certification	KGSP, SMEs Venture company, MAINBiz etc.

CURE PHARMTECH_Munsan factory

On the site of gross area of 2,290.95 m², we have obtained manufacturing system for animal drug and biodegradable polymer sutures. ('CURELINE') Also, we have been selected as corporate-affiliated research institute and animal medicine clinical trials laboratory.



Location	61, Donyu1-ro, Paju-eup, Paju-si, Gyeonggi-do (Sunyu Industrial Complex)
Major departments	Public service, Overseas sales, Clinical trials laboratory, Research institute
Full-time employees	13 people
Certification	ISO13485, Corporate-affiliated research institute, Animal medicine clinical trials laboratory
Production CAPA	Suture 8,000KM/YEAR

Introduction

CURE BIOTECH(SUBSIDIARY)

We produce 9 types of polymer chips such as PDO, PGA, PCL etc. which are the raw materials for polymer medical devices used for human body. (Product name: CURESORB)



Location	50-30, Hugi-gil, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungbuk
Major department	Production, QC, Accounting
Full-time employees	10 people
Certification	ISO13485
Production CAPA	8 tons or more of biodegradable polymer chips / YEAR

CURE BIOCHEM(SUBSIDIARY)

We produce glycolide (Product name: Cure-glycolide), the world's best quality biodegradable polymer base material.




Location	50-30, Hugi-gil, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungbuk
Major department	Production, QC, Accounting
Full-time employees	7 people
Certification	ISO9001
Production CAPA	More than 50 tons of glycolides and lactides / YEAR

Introduction

CURE ANICARE(SUBSIDIARY)

We specialize in distributing carefully selected medicines and foods for pets.



Location	#216, 20-38 Moogungwha-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do
Major department	Marketing, Sales, Accounting
Full-time employees	5 people
Certification	N/A

CURE F&B(SUBSIDIARY)

Produces the world's first noble protein feed with a strong immune function and essential amino acids from rice grasshoppers and dried pollock.




Location	1dong-1 st floor, 61-1, Jungri-gil 43bun-gil, Eumseong-eup, Eumseong-gun, Chungbuk
Major departments	Production, QC, Accounting
Full-time employees	6 people
Certification	IHACCP
Production CAPA	More than 1,000 tons of pet food and supplements / Year

Operational Division Introduction

- ORGANIZATION
- OPERATIONAL DIVISION INTRODUCTION

Organization

CURE PHARMTECH



Medical Business Part

Cure Pharmtech started as a company specializing in medicine, medical device sales and marketing.

Currently, we are actively in business with hundreds of clinic-level hospitals, large general hospitals, and university hospitals nationwide and has secured numbers of distributor contracts and contracts with local distributors.

Along with the current sales activities of medicines and medical devices, we not only conduct a leading product research overseas, but also, continuously develop and research products through corporate-affiliated research institute to ensure that patients and their families suffering from the disease can enjoy a healthy and happy life.

The representative distributed products are Immualpha, Prosealief, Polyerga, Mesima-F, Selenase, Immucothel, Calciferol, Conjuran, PRP etc.

We are also preparing to launch beauty products with combined medical and biopolymer technologies.



PRODUCT

PROSEALIEF



Prosealief helps to prevent skin damage from excessive moisture. Prosealief forms a protective layer on the surface of the skin allowing to prevent dermatitis and pressure sore due to incontinence.

IMMUALPHA



THYMOSIN A1, a main ingredient of Immualpha, is a strong immunomodulatory peptide essential to the body secreted from the thymus. Immualpha is used as adjuvant chemotherapy to boost patient's immunity by activating immune cells and suppressing infected cells and cancer cells.

IMMUCOTHEL



Immucothel promotes anti-cancer antibodies production via activation of immune cells.


ThyMD Capsule



ThyMD Capsule is a prescription-based medicine made of thymomodulin that promotes autoimmune health..

PRODUCT

LOOPFIX



Grade 1 medical device including both drainage fixing and wound closure function

Expected release date is in 2022

SKIN BOOSTER



Cosmetics for skin beauty made of a combination of biopolymer material and peptides

Expected release date is in 2023

Copper Oxide-Impregnated Wound Dressing



The copper oxide-impregnated wound dressing is a high-quality product that provides a protective barrier to a wide range of cuts and germs allowing fast recovery of wounds

Expected release date is in 2022

ShowerCherum Wash Glove



A convenient waterless shower glove that can be easily used in a difficult situation to take a shower.

Pet Business Part

Cure Pharmtech has chosen an animal medicine business worth of USD 36 billion in the global market as its new business.

We produce and distribute products that are beneficial to foundation of health which includes animal food and animal medicine so that both pets and their owners can enjoy a health life together.

In addition, the capability to develop animal medicines with its safety and efficacy has been verified through our corporate-affiliated research institute and animal clinical trials laboratory. Thus, we are actively contributing to the development of products for pets.

The representative products are GOOFOO; comprehensive nutritional pet food, jointAND; joint nutritional supplement, oralAND; oral care nutritional supplement, and Apocaps for cancerous dogs.



PRODUCT

GOOFOO



Product name GOOFOO

Details GOOFOO is a premium insect feed made safely using only 100% edible insect protein and natural ingredients. GOOFOO is formulated with various active ingredients that are beneficial to your dog's health, helping to balance nutrition, improve allergies, and boost immunity.

Ingredients Dried pollack, Silkworm pupa, Sugar cane, Germinated black rice, Broccoli, Rice grasshopper, Eastern prickly pear, Wood-cultivated ginseng

oralAND



Product name oralAND

Details OralAND is safely designed with naturally derived ingredients. OralAND, an oral pet care, reduces plaque formation and help to inhibit and relieve inflammation as well as boost immunity and improve the intestinal environment.

Ingredients Egg yolk, Lactoferrin, Eastern prickly pear, Nelumbo nucifera seed, Tea extracts, Kelp, Digestion-resistant maltodextrin, Inulin, Probiotics, Taurine

jointAND



Product name jointAND

Details JointAND is a pet joint nutritional treat that benefits joint health. It contains sufficient amount of ingredients that benefits joint health along with improvement on liver health.

Ingredients Green-lipped mussel, N-acetylglucosamine, Shark cartilage (Chondroitin), MSM, Boswellia, Hyaluronic acid, Wheatworm, Milk thistle, Hydrolyzed chicken

showerAND



Details

ShowerAND is a wash glove for pets designed for convenient shower.

It will be released as a disposable pack type with mixture of special fabric nonwoven glove, functional shower ingredients and beauty ingredients.

PRODUCT

- Animal medicine

POLYNA INJ.



Product name	POLYNA INJ.
Efficacy	Regeneration of wounds, restoration of tissues, and shortening the healing period of wounds.
Indications	Chronic pain, arthritis, ulcer and burn treatment, surgical wound treatment
Competitiveness	The only injection-type for wound treatment
Expected release date	2022

PERIMOSIN INJ.



Product name	PERIMOSIN INJ.
Efficacy	Increased immune cells such as NK-cell and T-cell, increased MHC-1 on the surface of tumor cells, and suppressed self-replication of viruses
Indications	Chronic pain, arthritis, ulcer and burn treatment, surgical wound treatment
Competitiveness	The only injection-type for wound treatment
Expected release date	2022

Biopolymer Business Part

The global market size of medical biopolymer reached about USD 10 billion as of 2019, and the annual growth rate is classified as a promising business group with a CAGR of 7~8%. Currently, the use of biopolymer is expanding in the overall field of medical device such as absorbent sutures, polymer fillers, implants and DDS (Drug Delivery System) etc. Due to the difficulties of manufacturing technology, medical biopolymer products are produced by only a few companies around the world.


The full process is divided into ① Basic raw material (powder form) ② material (solid grain form) ③ medical device (final product) and only very few companies around the world can produce via full process.

Cure Pharmtech is one of the few company that can conduct full process as described above, and has established separated corporations on each process and commercialization different types of products to strengthen its expertise in production.

The representative products are produced and distributed from raw materials of polymers such as PDO, PDO DYED, PCL, PLLA and PGA to final products.



Production of raw materials for biodegradable polymers



Production of raw materials for biodegradable polymers

Cure Biochem produces glycolides and lactides as the basic raw material of biodegradable polymer medical device.

Glycolides and lactides requires a high technology and process management. Therefore, only very few companies around the world have the technology to produce these products.



High-quality basic raw materials

<u>CERTIFICATE OF ANALYSIS</u>				
Product Name : CureGlycolide				
LOT No. : CG21008				
Material : Glycolide (1,4-Dioxane-2, 5-dione)				
Production Date : 12-July-2021				
<u>Characteristics</u>	<u>Standard</u>	<u>Method</u>	<u>Value</u>	<u>Remarks</u>
Free Acid	$\leq 1.0\text{meq/kg}$	Mettler Toledo T5	0.073meq/kg	Pass
Moisture Content	$\leq 100\text{ppm}$	Karl-Fischer	66.1ppm	Pass

0.073meq/kg

Cure Biochem's glycolides and lactides are under production management regulation of ISO13485.


Our glycolides and lactides retains a higher purity of under 1 MEQ than the basic raw material quality standards of 3.5 MEQ used for medical purposes.

Cure's differentiated production method enables production of high-quality products.



Based on our excellent quality of the product, we are currently exporting overseas with large domestic medical device manufacturers, especially through annual supply contracts with large medical device manufacturers. In 2022, we aim to strengthen our position in domestic and overseas as a supplier of rare biopolymer basic raw material through the development of D-type lactide and DL-type lactide.

Production of biodegradable polymer materials



Biodegradable polymer materials

All biodegradable medical devices and medicines require PALLET type materials such as Cure Biotech's CURESORB.


Cure Biotech's CURESORB supplies products to domestic and foreign companies with stability (GLP data acquisition) tailored to the properties desired by customers.





Cure Biotech produces all copolymers such as PLCL, PGCL and PGLA and single polymers such as PDO, PGA, PCL and PLLA. We carry all the ingredients related to biodegradable medical devices.

We are expanding our spectrum as a supplier of biodegradable basic raw material through the success of the first development and commercialization of PDCL and PLDA copolymer.



Cure Biotech supplies products to domestic and overseas companies.

Cure Biotech has been recognized for its quality and stability via acquiring all the strict supply conditions of large medical device manufacturers in China, India, England, France and Germany etc.

Therefore, export-oriented sales are taking place through stable product supply.

Microsphere

Microspheres are collectively referred to as fine spherical particles with a diameter of less than 100 microns (1 micron = 0.001 millimeter in size) and are currently used in drug delivery systems (DDS) and as a material for polymer fillers in the medical field.

* Main ingredients such as PCL, PGLA, and PDLA (D-type lactide) etc.

Microsphere






Image source from Cure Pharmtech Co., Ltd.

Cure Pharmtech possesses production technology for high purity biopolymer, a main ingredient of microspheres, and has completed test production with microsphere production techniques.

Cure Pharmtech is planning for mass production through additional facilities.

Production of Biodegradable Polymeric Suture



CURELINE is a biodegradable suture that is produced through the whole process production as world's 10th biodegradable suture production company.
CURELINE has secured its high quality and safety as a suture in the USD 5.1 billion global market.
We plan to challenge the global market with total of six product lines including the world's first PDCL suture.
(2020 government project acquisition)

The World's 10th Biodegradable Suture Production Company



CURELINE is a biodegradable suture, the world's 10th biodegradable suture, that is produced through the whole process production (GLP data acquisition)

CURELINE has secured its high quality and safety as a suture in the USD 5.1billion global market.

We plan to target the global market with a total of six product lines including the world's first PDCL suture.
(2020 government project acquisition)

Production of Biodegradable Polymeric Suture



CURELINE PDO

Polymer Structure : Poly(P-Dioxanone)

Type : Monofilament

Size : 7-0~3,4

Length : 500M, 1000M

Period : 6 months



CURELINE PLLA

Polymer Structure : L-Lactide

Type : Monofilament

Size : 7-0~3,4

Length : 500M, 1000M

Period : 18~20 months



CURELINE PCL

Polymer Structure : ϵ -Caprolactone

Type : Monofilament

Size : 7-0~3,4

Length : 500M, 1000M

Period : 22~24 months



CURELINE PLCL

Polymer Structure : L-Lactide-co- ϵ -Caprolactone

Type : Monofilament

Size : 7-0~3,4

Length : 500M, 1000M

Period : 10~12 months



CURELINE PGCL

Polymer Structure : Glycolic acid-co- ϵ -Caprolactone

Type : Monofilament

Size : 7-0~3,4

Length : 500M, 1000M

Period : 90~110 days

NEW



CURELINE PDCL

Polymer Structure : P-Dioxanone-co- ϵ -Caprolactone

Type : Monofilament

Size : 7-0~3,4

Length : 500M, 1000M

Period : 120~180 days

NEW



CURELINE PLD

Polymer Structure : Poly(P-Dioxanone-co-L-Lactide)

Type : Monofilament

Size : 7-0~3,4

Length : 500M, 1000M

Period : 540~110 days

NEW



CURELINE SKIN PDO

Polymer Structure : Poly(P-Dioxanone)

Type : Monofilament

Size : 7-0~3,4


Color : ●

Length : 500M, 1000M

Period : 180~240 days

Functional suture (DDSLINE)

DDSLINE is the first drug delivery technology that contains drug material in an absorbable suture. It is applicable to the market in the fields of surgical surgery or cosmetic plastic surgery (application for domestic and foreign patents).



DDSLINE-DR

Functional suture with tissue regeneration substances

Product name DDSLINE-DR

Ingredients POLY [P-DIOXANONE]+Tissue regeneration factor

Development Background The first drug delivery system utilized suture. - The absence of a product with a safe and rapid tissue regenerating suture in the area of lifting procedures.

Strengths - Not simply coated on the surface but tissue regenerating substances are evenly distributed within the suture which enables consistent release of tissue regenerating substances when decomposed in the body.

DDSLINE-DM

Functional suture with moisturizing substances

Product name DDSLINE-DM

Ingredients POLY [P-DIOXANONE]+Moisturizing factor

Development Background Addition of HA's moisturizing function to existing cosmetic suture. Maximizes skin moisturization by supplying HA within the body.

Strengths Continuous HA supply within the skin up to 8 months. ▶ Long-term moisturizing effect

DDSLINE-DA

Functional suture with anti-inflammatory substances

Product name DDSLINE-DA

Ingredients POLY [P-DIOXANONE]+Anti-Inflammatory factor

Development Background Developed with the purpose of managing inflammation in the suturing after surgery.

Strengths Surgical suture that is safe from inflammation. No additional medical treatment is required to manage inflammation at the surgical site.

DDSLINE-DF

Functional suture with fat reducing substances

Product name DDSLINE-DF

Ingredients POLY [P-DIOXANONE]+Fat removal factor

Development Background Addition of fat reducing function to existing cosmetic suture. Noticed the market's need for products that have both lifting and fat-reducing effects.

Strengths Continuous fat reducing effect within the skin up to 8 months. Enables fat-reducing effects in the areas where fat removal is difficult with the release of functional drug material.

Cure Pharmtech Technologies

큐어팜텍 DO210615A1-00W_#1_EP_PDO Date: 2021-06-21 Time: 09:43:50



Company Information
Name: [Redacted]
Address: [Redacted]
Tel: [Redacted]
Specification: [Redacted]

Test NO. [Redacted]
Test Date 2021-06-15
Diameter 0.47 mm

Test Speed 300 mm/min
Gauge Length 200 mm

Data Table

Item1	F max	F max	σ max	Eg max
Item2	인장강도	인장강도	인장강도	인장률
Unit	N	kgf	kgf/cm ²	%
1	54.1	5.5	3188.621	48.883
2	54.3	5.5	3200.167	49.132
3	55.3	5.6	3258.363	49.132
4	54.2	5.5	3193.603	49.674
5	54.6	5.6	3217.449	49.374
Max	55.3	5.6	3258.363	49.674
Min	54.1	5.5	3188.621	48.883
Mean	54.5	5.5	3211.641	49.299
Stdev	0.5	0.1	25.300	0.415



GLP REPORT

TEST FACILITY
[Redacted]
[Redacted]
[Redacted]

STUDY TITLE
[Redacted]

TEST ARTICLE NAME
[Redacted]

TEST ARTICLE IDENTIFICATION
[Redacted]

GLP REPORT

TEST FACILITY
[Redacted]
[Redacted]
[Redacted]

STUDY TITLE
[Redacted]

TEST ARTICLE NAME
[Redacted]

TEST ARTICLE IDENTIFICATION
[Redacted]

큐어팜텍 DO210607A1-00W+PDRN_#1_EP Date: 2021-06-21 Time: 09:25:57



Company Information
Name: [Redacted]
Address: [Redacted]
Tel: [Redacted]
Specification: [Redacted]

Test NO. [Redacted]
Test Date 2021-06-07
Diameter 0.47 mm

Test Speed 300 mm/min
Gauge Length 200 mm

Data Table

Item1	F max	F max	σ max	Eg max
Item2	인장강도	인장강도	인장강도	인장률
Unit	N	kgf	kgf/cm ²	%
1	54.0	5.5	3185.629	49.726
2	49.5	4.9	2956.989	37.240
3	54.6	5.6	3216.605	41.489
4	59.2	6.0	3488.076	44.257
5	59.6	6.0	3537.731	42.590
6	55.0	5.6	3242.188	41.769
Max	59.2	6.0	3488.076	44.257
Min	49.5	4.9	2956.989	37.240
Mean	54.7	5.6	3221.589	41.337
Stdev	5.5	0.4	200.688	2.340




elasticity and strength Test

UV Test

Electron Microscope Magnification Picture

The Safest Test



Emission Test

Even with the 2% of the drug contained, the strength and elasticity of the existing suture were maintained. CURE PHARMTECH has already produced "DDSLINE" products that already possess its efficacy and safety data through various tests, and it is in the process of patent application.

R&D and Clinical trials

- Corporate-affiliated Research Institute
- Animal Medicine Clinical Trials Laboratory

Cure Pharmtech Corporate-affiliated Research Institute



Establishment

- 20. 07 Acknowledgement of Corporate-affiliated Research Institute
- 21. 01 Applied for a company designated for military service

Management

- Director of Research Institute (Doctor of Pharmacy)
- Senior level 2 people
- Veterinarian 1 person



Government project

- Gyeonggi-do technology development project
: Development of PDCL-based absorbable monofilament suture
- Conditional Purchase Project for New Product Development
: Development of new absorbable PLDA Monofilament

R&D

- Development of biodegradable biopolymer material
- A study on the formulation of new anticancer aid immunity-boosting injection for animal
- A study on the formulation of new wound treatment injection for animal
- Research on candidates of natural ingredients for hair growth

CURE PHARMTECH Clinical trials laboratory



Facilities Clinical medicine storage, Specimen treatment/storage, Document storage

History

- 20. 09 Applied for clinical trial institute
- 21. 01 Animal and Plant Quarantine Agency on-site inspection
- 21. 03 Supplementation to SOP
- 21. 04 Approval of clinical trial institute expected

Government project Conduction of clinical trials for new animal drugs and re-evaluation in cooperation with animal hospitals

Certification and Authorization

Certification And Authorization

In recognition of its business capabilities and technology, Cure Pharmtech has obtained quality management systems (ISO13485, ISO9001) and is certified for promising export SMEs, Gyeonggi SMEs, SMEs Venture Business, and MainBiz. For continuous investment in research and development, such as corporate affiliated research institutes and the designation of clinical trial institutions, and for the security of core technologies, patent acquisition and application are in process.



National Research Project

Cure Pharmtech has carried out a number of biopolymer-related national projects supported by government agencies.

- 경기도 경제발전을 선도하는 혁신성장의 촉진자, GBSA -



경기도경제과학진흥원



수신자 (주)큐어팜텍
(경유)

제목 2019년 2/3차 경기도 기술개발사업 최종평가 결과통보

1. 귀사의 무궁한 발전을 기원합니다.
2. 관련근거
 - 가. 경기도 기술개발사업 운영요령 제32조 (평가 및 이의 절차)
 - 나. 경기도 기술개발사업 운영요령 제40조 (사업 종료 후 활용 보고 및 평가)
 - 다. 경기도 기술개발사업 관리지침 제33조 (기술개발결과의 공개)
 - 라. 경기도 기술개발사업 관리지침 제34조 (성과활용평가)
3. 귀사에서 수행한 경기도 기술개발사업 과제에 대한 최종평가 결과 **"성공(보통)"**으로 결정되었음을 알려 드립니다.
4. 또한 세부 평가결과 및 협조사항을 붙임과 같이 안내드리오니 본 사업이 원활히 마무리 될 수 있도록 **항후 일정에 적극 협조**하여 주시기 바랍니다.

붙임 : 2019년 2/3차 경기도 기술개발사업 최종평가 결과안내 1부. 끝.

경기도경제과학진흥원장



구매조건부신제품개발 표준협약서(구매연계형)

- ☐ 사 업 명 : 구매조건부신제품개발사업(구매연계형)
- ☐ 과 제 명 : 새로운 PLDA 흡수성 monofilament 개발
- ☐ 총 기술개발기간 : 2020년 10월 20일 ~ 2022년 10월 19일 (총 24 개월)



중소기업기술정보진흥원
Korea Technology and Information Promotion
Agency for SMEs

THANK YOU

INFO@CUREPT.KR

www.curept.kr